Michael Tappin KC, sitting as a deputy judge of the High Court, refused to grant AstraZeneca (“AZ”) an interim injunction ...

AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines across various therapeutic areas, including diabetes.

AstraZeneca will pay Bristol-Myers Squibb US $3.4 billion in cash, and the companies will share profits and losses. “Amylin’s innovative diabetes portfolio, talent people and state-of-the-art ...

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires.In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best ...